Company Filing History:
2 out of 443 
2 out of 2,963 
1 out of 118 
Years Active: 2015-2020
Title: Zarko Boskovic: Innovator in Cancer Therapy
Introduction
Zarko Boskovic is a prominent inventor based in Cambridge, MA, known for his significant contributions to cancer therapy. With a total of two patents, he has focused on developing innovative methods and compositions for treating multiple myeloma and other cancers. His work is characterized by a commitment to advancing medical science and improving patient outcomes.
Latest Patents
Boskovic's latest patents include groundbreaking methods for treating multiple myeloma. One patent details a method of inhibiting the proliferation of multiple myeloma cells by contacting them with BRD9647. This method is particularly significant as it targets specific mutations in the AZIN1 polynucleotide or polypeptide, allowing for personalized treatment approaches. Another patent focuses on compounds and compositions for cancer therapy, specifically highlighting various oligomers of piperlongumine and their analogues that exhibit improved toxicity to cancer cells. These innovations represent a substantial advancement in the field of oncology.
Career Highlights
Throughout his career, Zarko Boskovic has worked with esteemed institutions such as the Broad Institute, Inc. and Harvard College. His experience in these prestigious organizations has allowed him to collaborate with leading experts in the field and contribute to cutting-edge research in cancer treatment.
Collaborations
Boskovic has had the opportunity to work alongside notable colleagues, including Stuart L. Schreiber and Drew Adams. These collaborations have further enriched his research and have played a crucial role in the development of his innovative therapies.
Conclusion
Zarko Boskovic's work in cancer therapy exemplifies the impact of innovation in medicine. His patents and research efforts are paving the way for more effective treatments for patients suffering from multiple myeloma and other cancers. His contributions to the field are invaluable and continue to inspire future advancements in cancer research.